Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy

Correction to: British Journal of Cancer (2008) 99, 1050–1055; doi:10.1038/sj.bjc.6604671

Upon publication of the above manuscript in Volume 99 of BJC, the authors noted a small error in the affiliations of L Paré, E del Rio, A Cortés and M Baiget. The full affiliations (addition in bold) is now shown below.

L Paré¹, E Marcuello², A Altés³, E del Río^1,4, L Sedano⁴, J Salazar⁴, A Cortés¹, A Barnadas² and M Baiget^1,4

¹Department of Genetics, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona 08025, Spain; ²Department of Clinical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona 08025, Spain; ³Department of Hematology, Fundació Althaia, Manresa, Spain; ⁴Center for Biomedical Research on Rare Diseases (CIBERER), Barcelona 08025, Spain